In more than 262,000 UK Biobank participants, a 5-marker cardiometabolic score was linked to graded risk at each step toward CKM multimorbidity.

In pooled CORALreef data, patients with eGFR below 60 had a 65.9% placebo-adjusted LDL-C reduction at week 24, with safety comparable to placebo.

Two IDWeek 2026 studies link influenza vaccination to fewer ICU admissions in older adults and fewer emergency visits in children.

The approval offers a once-weekly basal insulin treatment option for patients, reducing the frequency of injections.

Early data suggest the 7 PCV20-added serotypes are causing a smaller share of invasive pneumococcal disease in children younger than 2 years.

Pharmacy Times will feature experts on kidney function assessment, IgG4-related disease, emerging CKD therapies, and gaps in cardiorenal care.

REDEFINE 1 analyses presented at The Menopause Society 2026 meeting found mean weight loss of 23.1% to 26.7% across pre-, peri-, and postmenopausal women.

Mounjaro becomes the first GIP/GLP-1 receptor agonist cleared to lower MACE risk, based on the SURPASS-CVOT head-to-head trial.